<DOC>
	<DOCNO>NCT00964184</DOCNO>
	<brief_summary>This phase IV study 3.5 year duration evaluate phenotypic genetic correlate diabetes ( non-Type 1 young non-obese Asian Indians North India pilot case control study evaluate efficacy sitagliptin ( DPP-4 inhibitor ) sub-group study population .</brief_summary>
	<brief_title>Phenotypic Genetic Correlates Diabetes ( Non-Type 1 ) Young Non-Obese Asian Indians North India A Study Evaluate Efficacy Sitagliptin ( DPP-4 Inhibitor ) Sub-group Study Population</brief_title>
	<detailed_description>A phase IV T2DM BMI &lt; 25 kg/m2 age 14-40 year . Primary Objectives : - To investigate phenotype ( body composition , anthropometry , pancreatic imaging endocrine function , insulin resistance , autoantibody , biochemical variable ) genetic ( know mutation polymorphism ) correlate young ( age 14-40 year ) diabetic patient ( non-type 1 ) . Secondary Objectives : - To study anthropometric body fat distribution include truncal fat , subcutaneous intra-abdominal fat non-obese young patient diabetes ( non-type 1 ) . - To study whether insulin secretion , insulin resistance combination is/are predominant defect ( ) non-obese young diabetic ( non-type 1 ) . - To study prevalence autoimmunity and/or specific genetic abnormality subgroup diabetic . - To estimate approximate prevalence diagnostic subcategories base sample population , profile complication category . - To propose rational use specialized investigation ( e.g . GAD65 , HNF-1α mutation etc ) investigate newly diagnose young diabetic . - To determine rational therapeutic option prognosis sub-population diabetic base anthropometric , biochemical , etiological profile . - Sample size : 205 patient enrol 120 patient enrolled sub group study</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Young ( 18 40 year ) patient diabetes ( insulin therapy ) past 6 month BMI &lt; 25 kg/m2 . Drug naïve patient Patients monotherapy metformin ( &lt; 1g/day ) . Type 1 diabetes Type 2 Diabetes oral hypoglycemic agent metformin Pregnancy lactation Insulin Sulfonylurea treatment within past 3 month Has receive investigational drug past 60 day History prior allergy hypersensitivity drug ( unless approve investigator ) HbA1c &lt; 7.5 % &gt; 8.5 % . Unstable glycemic control , require addition 2nd oral agent/insulin frequent uptitration dose metformin . Any patient insulin . Females child bear potential use adequate contraception study period . Insulin dependent history ketoacidosis require hospitalization Acute infection Advanced endorgan damage ( CLD , CRF etc . ) Diabetes clinically significant advance endorgan damage</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Maturity onset diabetes young 3 protein , human</keyword>
</DOC>